SureTrader SureTrader
Home > Boards > US Listed > Biotechs >

ChemoCentryx (CCXI)

CCXI RSS Feed
Add CCXI Price Alert      Hide Sticky   Hide Intro
Moderator: FutureEnergy
Search This Board:
Last Post: 9/22/2016 10:45:45 AM - Followers: 22 - Board type: Free - Posts Today: 0


ChemoCentryx is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. The Company targets the chemokine system, a network of molecules, including chemokine ligands and their associated receptors, as well as related chemo-attractant receptors, all of which are known to drive inflammation.



Board of Directors

Thomas J. Schall, Ph.D.President, Chief Executive Officer and Chairman of the Board
Dr. Schall is the founder of our company and has served as our President, Chief Executive Officer and Director since we commenced operations in 1997 and was appointed Chairman of the Board in April 2012. From 1993 to 1997, Dr. Schall worked at the DNAX Research Institute, a division of Schering-Plough Corporation, a pharmaceutical company. Prior to his work at the DNAX Research Institute, he worked as a scientist with Genentech, Inc., a pharmaceutical company. Dr. Schall participated in some of the earliest discoveries of chemokine system function and activities. Dr. Schall cloned one of the first chemokines to be discovered, and provided some of the earliest data for the existence of the previously unknown family of molecules which later came to be called the chemokines. Dr. Schall’s laboratories have been responsible for the discovery or co-discovery of a large percentage of all known chemokine receptors. Dr. Schall received his B.S. in biology from Northern Illinois University and his Ph.D. in cancer biology from Stanford University.

Thomas A. EdwardsRetired Partner, Latham & Watkins, LLP
Thomas A. Edwards has served on our board of directors since July 2015. Until his retirement in March 2014, Mr. Edwards practiced law with Latham & Watkins LLP, an international law firm, since 1983, having become partner in January 1991. His practice focused on general corporate and securities law, including capital financings, acquisitions, divestitures and spin-offs of companies and partnerships. Mr. Edwards earned his bachelor’s degree from Harvard College and his law degree from Harvard Law School.

Joseph M. Feczko, M.D.Former Senior Vice President and Chief Medical Officer, Pfizer Inc.
Dr. Feczko has served on our board of directors since April 2012. Until his retirement in May 2009, Dr. Feczko was Senior Vice President and Chief Medical Officer of Pfizer Inc. and a member of its Executive Leadership Team with global responsibilities for all aspects of the company’s medical, regulatory and safety activities. Dr. Feczko served Pfizer in both New York and the United Kingdom since 1982, where he held positions of increasing responsibility in clinical research and regulatory affairs and safety, culminating in the role of Chief Medical Officer. Dr. Feczko is board-certified in Internal Medicine and Infectious Diseases. He has a B.S. degree from Loyola University Chicago, and an M.D. from the University of Illinois College of Medicine. Dr. Feczko also serves on the board of directors of Keryx Biopharmaceuticals, Inc. and Cytheris, SA. Dr. Feczko also serves as chairman of the board of directors of Cardoz Pharmaceuticals AB (Stockholm, Sweden) and as a member of the Supervisory Board of uniQure B.V., based in the Netherlands.

Roger C. Lucas, Ph.D.Vice Chairman, Bio-Techne Corporation
Dr. Lucas has served on our board of directors since September 1997. Since 1995, Dr. Lucas has served as Vice Chairman and a member of the board of directors of Bio-Techne, formerly Techne Corporation, a biotechnology company. From 1985 to 1995, Dr. Lucas served as the Chief Scientific Officer, Senior Executive Vice President and Secretary of Bio-Techne Corporation and the founder of its Biotechnology Division. Prior to this, Dr. Lucas was Vice President of Research at R&D Systems, now a subsidiary of Bio-Techne, where he worked for over ten years. Dr. Lucas received his B.S. in biology and chemistry from St. Mary’s College, Minnesota and his Ph.D. in physiology and cell biology from Illinois Institute of Technology. Dr. Lucas also presently serves on the board of directors of a number of privately held companies.

Geoffrey M. ParkerFormer Executive Vice President and Chief Financial Officer, Anacor Pharmaceuticals, Inc.
Mr. Parker has served on our board of directors since December 2009. From September 2010 to May 2015, Mr. Parker was Chief Financial Officer of Anacor Pharmaceuticals, Inc. after serving in a consulting capacity since December 2009. From July 2009 to July 2010, Mr. Parker served in a consulting capacity as the Chief Business Officer of InteKrin Therapeutics, Inc. a biotechnology company and previously served as Managing Director and Partner in the Investment Banking Division of Goldman, Sachs & Co. From 1997 to 2009, Mr. Parker directed Goldman Sachs’ West Region Healthcare Investment Banking practice. From 1995 to 1997, Mr. Parker was Vice President at Feibusch & Co., a venture capital firm. Mr. Parker received his A.B. in Engineering Sciences and Economics from Dartmouth College and his M.B.A. from Stanford University.

James L. TyreeFormer Executive Vice President, Abbott Laboratories
Mr. Tyree has served on our board of directors since June 2012. Mr. Tyree is the co-founder and managing partner of Tyree & D’Angelo Partners, a private equity investment firm. During the last fifteen years, Mr. Tyree has held numerous executive positions at Abbott Laboratories, including Corporate Vice President Pharmaceutical and Nutritional Products Group Business Development, Senior Vice President Global Nutrition and Executive Vice President Global Pharmaceuticals. He retired as President of Abbott Biotechnology Ventures in March 2012. Prior to joining Abbott, Mr. Tyree was the President of SUGEN, Inc., a biotechnology company focused on oncology. Earlier in his career, Mr. Tyree held management positions in Bristol-Myers Squibb, Pfizer and Abbott. Over his entire career, he was a four-time expatriate living and working over six years in Latin America and seven years in Japan. Mr. Tyree is a member of the Advisory Board of the University of Chicago Booth Graduate School of Business, a member of the Chicago Council on Global Affairs and co-chairman of the Global Health Policy Roundtable. Mr. Tyree also serves as a director for a number of privately held companies. Mr. Tyree earned Bachelor’s Degrees in Psychology and Forensic Studies and a Master’s Degree in Business Administration from Indiana University.


Shares outstanding 44.073.659 a/o Aug 2015
Authorized shares 200.000.000
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CCXI
Current Price
Volume:
Bid Ask Day's Range
SureTrader
CCXI News: Confidential Treatment Order (ct Order) 09/16/2016 03:08:32 PM
CCXI News: Statement of Changes in Beneficial Ownership (4) 09/02/2016 05:48:01 PM
CCXI News: ChemoCentryx Reports Initial Results from Ongoing Phase Ib Clinical Trial of CCX872 in Patients with Advanced Pancreatic Canc... 09/01/2016 04:05:00 PM
CCXI News: Amended Statement of Beneficial Ownership (sc 13d/a) 08/25/2016 04:36:00 PM
CCXI News: ChemoCentryx to Present at the Baird 2016 Global Healthcare Conference 08/25/2016 08:30:00 AM
PostSubject
#139  Sticky Note ChemoCentryx Receives European Medicines Agency PRIority MEdicines (PRIME) FutureEnergy 06/01/16 09:13:59 AM
#165   Confidential Treatment Order (ct Order) FutureEnergy 09/22/16 10:45:45 AM
#164   Must read.... I was surprised about the Friday FutureEnergy 09/06/16 10:30:09 AM
#163   welcome back 5's :-) still nothing if you FutureEnergy 08/31/16 09:12:12 AM
#162   Slow but steady back to $ 5... FutureEnergy 08/25/16 10:26:26 AM
#161   Any insight on what's going on here since REDEMPTIVE 08/09/16 03:15:22 PM
#160   New news will come out in the next FutureEnergy 07/28/16 03:04:43 PM
#159   Company needs to get some news out on REDEMPTIVE 07/25/16 02:25:07 PM
#158   Ron yes , well I still have Whalatane 07/16/16 10:42:54 AM
#157   Anyone still here? ronpopeil 07/15/16 01:41:33 PM
#156   Bought in yesterday. CCXI getting hit because biotech ronpopeil 07/14/16 11:02:53 AM
#155   $ 4.8? it's a joke :-) Im am FutureEnergy 07/10/16 11:59:34 AM
#154   I think once our big seller @4.8 is FutureEnergy 06/17/16 09:46:52 AM
#153   FE ..its sell the news. Whalatane 06/16/16 11:48:39 AM
#152   funny, like always down on good news... think FutureEnergy 06/16/16 09:32:42 AM
#151   ChemoCentryx Announces Positive Top-Line Results for CCX168 from FutureEnergy 06/16/16 09:18:09 AM
#150   CCXI bullish 5.08 stocktrademan 06/03/16 07:55:37 PM
#149   Important is that we get the Track in FutureEnergy 06/03/16 09:41:53 AM
#148   Well next up CLASSIC data and possible US Whalatane 06/02/16 10:07:20 PM
#147   YW! I am in Europe, and my sister-in-law FutureEnergy 06/02/16 03:04:16 PM
#146   FutureE Thx for posting this EU Fast Track Whalatane 06/02/16 12:23:34 PM
#145   Agreed! tjguy 06/02/16 10:11:26 AM
#144   Yep oops it did not... strange trading yesterday, FutureEnergy 06/02/16 08:08:06 AM
#143   relax, we will be close to $6 by EOD tjguy 06/02/16 04:30:40 AM
#142   relax, we will be close to $6 by FutureEnergy 06/01/16 10:00:03 AM
#141   Sell the news I guess? REDEMPTIVE 06/01/16 09:45:39 AM
#140   Kaboooooooooooooooooooom! here we go ! FutureEnergy 06/01/16 09:15:21 AM
#139   ChemoCentryx Receives European Medicines Agency PRIority MEdicines (PRIME) FutureEnergy 06/01/16 09:13:59 AM
#138   CCXI 5.88 NEWS PAC 06/01/16 08:35:42 AM
#137   If we can close above 5.5 today we FutureEnergy 05/31/16 11:24:27 AM
#136   Thanks. tjguy 05/28/16 02:52:27 AM
#135   TJ. They have Orphan status already so I Whalatane 05/27/16 06:05:18 PM
#134   Tj re fast track status Usually reserved for Whalatane 05/27/16 05:45:36 PM
#133   * * $CCXI Video Chart 05-27-16 * * ClayTrader 05/27/16 05:04:05 PM
#132   love it!!! FutureEnergy 05/27/16 12:02:13 PM
#131   CCXI above 5, squeezing PAC 05/27/16 11:47:59 AM
#130   Push the shorts over 5.00 today and hold REDEMPTIVE 05/27/16 11:28:31 AM
#129   come on shortieeees cover :-) FutureEnergy 05/27/16 11:05:42 AM
#128   4.9 and climbing ! FutureEnergy 05/27/16 11:02:27 AM
#127   ha already there :-) :-) FutureEnergy 05/27/16 10:13:27 AM
#126   hopla here we go :-) maybe 4.7 to FutureEnergy 05/27/16 10:06:41 AM
#125   i dont know, but if they have, they FutureEnergy 05/26/16 09:28:13 AM
#124   Are they applying for fast track right now? tjguy 05/25/16 05:26:11 AM
#123   Whalatane is more or less correct about the FutureEnergy 05/24/16 09:05:15 AM
#122   I got the two mixed up. It tjguy 05/24/16 06:30:33 AM
#121   That was data from the CLEAR trial ...will Whalatane 05/23/16 09:51:04 PM
#120   Oh. I thought this was the June tjguy 05/23/16 09:21:14 PM
#119   tiguy They are at least 2 yrs Whalatane 05/23/16 08:01:22 PM
#118   200 mil... thats even only wat they tjguy 05/23/16 07:16:01 PM
#117   @ thise price levels CCXI is only worth FutureEnergy 05/23/16 10:05:05 AM
#116   ChemoCentryx Announces Presentation of Positive Results from Phase FutureEnergy 05/23/16 09:54:04 AM
PostSubject